Navigation Links
Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results
Date:8/23/2010

EXTON, Pa., Aug. 23 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY), a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its three months and fiscal year ended June 30, 2010.  

Fourth Quarter Snapshot and Recent Developments

  • Revenue of $21.9 million for the quarter, exceeding the high end of the Company's previous guidance range of $21.4-$21.8 million.
  • Record net sales of $15.1 million, exceeding previous guidance of $14.5-$14.7 million.
  • Royalty income of $6.8 million, below previous guidance of $6.9-$7.1 million.
  • Record diluted EPS and adjusted diluted EPS* of $0.60 and $0.54, respectively, exceeding the high end of previous guidance of $0.51-$0.53.
  • EBITDA* of $11.0 million.
  • Operating margin of 42%.
  • Operating cash flow of $10.9 million.
  • U.S. launch of first ECM product, the XCM Biologic™ Tissue Matrix, by strategic partner Synthes.
  • Received 510(k) clearance from the U.S. Food and Drug Administration for its second extracellular matrix (ECM) product, the Meso BioMatrix™ product.
  • New two-year collagen supply agreement with St. Jude Medical.
  • ECM strategic distribution agreement with Arthrex for sports medicine tendon repair and small joint surgeries.

  • Full Year Fiscal 2010 Financial Overview

  • Revenue of $80.6 million, meeting the high end of the Company's previous guidance range of $80.2-$80.6 million.
  • Net sales of $54.3 million, exceeding previous guidance of $53.6-$53.8 million
  • Royalty income of $26.4 million, below previous guidance of $26.5-$26.7 million
  • Record full fiscal year diluted EPS and adjusted diluted EPS* of $1.78 and $1.85, respectively, exceeding the high end of previous guidance for diluted EPS and
    '/>"/>

  • SOURCE Kensey Nash Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Kensey Nash Announces IDE Submission for Cartilage Repair Device
    2. Kensey Nash Announces Presentations on its Cartilage Repair Device at the International Cartilage Repair Society Meeting
    3. Kensey Nash Corporation Announces Its First Quarter Fiscal Year 2010 Earnings Release Date and Teleconference
    4. Kensey Nash Reports Second Quarter Fiscal Year 2010 Financial Results
    5. Kensey Nash Receives FDA 510(k) Clearance for Porcine Dermis Biologic Product
    6. Kensey Nash Announces $30 Million Share Buyback
    7. Kensey Nash to Present at the Canaccord Adams Musculoskeletal Conference
    8. Kensey Nash To Participate in the Sidoti Fourteenth Annual New York Emerging Growth Institutional Investor Forum
    9. Kensey Nash Corporation Announces the Addition of Donald Morel, Jr., Ph.D. to Its Board of Directors
    10. Kensey Nash to Present at the Ninth Annual JMP Securities Research Conference
    11. KENSEY NASH Receives FDA 510(k) Clearance for ECM Product, Meso BioMatrix Surgical Mesh
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)... 2015 Quietly, sedately, Morocco,s pharmaceutical ... domestic pharmaceutical industry is strong, with a well-developed base ... international standards. One place where the quality ... Africa: Morocco has quietly become the second largest African ... . Indeed, Moroccan pharma companies have been making ...
    (Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
    (Date:7/31/2015)... , July 31, 2015 ... solutions for video, data and cloud computing operators ... a leading pharma giant for Internet of Things ... IoT applications offered on subscription model. ... Pharma giant is striving for business innovations to ...
    Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
    ... YORK, Oct. 6, 2011 Reportlinker.com ... report is available in its catalogue: ... Market to 2017 - Patent Expiry ... Impact Dyslipidemia Market Value ...
    ... NEW YORK, Oct. 6, 2011 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0254328/The-Future-of-European-Pharmaceutical-Distribution.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical ... to reduce internal costs for manufacturers, and ...
    Cached Medicine Technology:Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 2Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 3Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 4Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 5Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 6Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 7Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 8Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 9Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 10Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 11Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 12Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 13Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 14Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value 15The Future of European Pharmaceutical Distribution 2The Future of European Pharmaceutical Distribution 3The Future of European Pharmaceutical Distribution 4The Future of European Pharmaceutical Distribution 5The Future of European Pharmaceutical Distribution 6The Future of European Pharmaceutical Distribution 7The Future of European Pharmaceutical Distribution 8The Future of European Pharmaceutical Distribution 9
    (Date:7/31/2015)... ... July 31, 2015 , ... Recently, ZKB filed ... Ohio, Western Division (Case No. 3:15-cv-00397) involving the Implanon® contraceptive implant . ... migration of their Implanon® implants, inability to locate the implants, unsuccessful and invasive ...
    (Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... The alarm was ringing. Hugh Chatfield, survivor ... out of the window, he recalled that his equipment was set up to depict the ... he jumped out of bed. , The photo speaks for itself. Chatfield is also a ...
    (Date:7/31/2015)... ... July 31, 2015 , ... Patients with higher levels of ... study published today in Nature Communications and led by researchers from the Icahn School ... variations in the gene RTN1 led to greater production of the related RNT1 protein, ...
    (Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... proud to announce that their latest designer handbag line will be named for ... an Internet sensation as the first globally recognized model with Down syndrome, gracing ...
    (Date:7/31/2015)... ... July 31, 2015 , ... Healthpointe ... a newly redesigned website at Healthpointe.net. The new website will feature a sleek ... The redesign serves to provide smoother interactions between patients and the Healthpointe clinics ...
    Breaking Medicine News(10 mins):Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:Healthpointe Announces Newly Redesigned Website 2
    ... Center have found a new technique that employs RNA, a ... lead to therapeutics// for conditions in which nudging a gene ... with a novel research tool to investigate the role that ... paper appearing online at Nature Chemical Biology and in an ...
    ... right type of fat may actually keep child obesity at ... unsaturated fat and very little omega-3. ,A study ... was undertaken by scientists at Goteborg University. These children belong ... revealed that 23% of the children belong to an overweight ...
    ... MPs, members of the Committee of Public Accounts, has come out ... ,Levels of obesity in children aged two to 10 years ... 2004, according to the Health Survey for England. , ... as obese. ,The Public Accounts Committee report ...
    ... Boston ranked the top city in America for having a ... conducted by Fit Pregnancy magazine, Boston’s outstanding// healthcare resources is ... like low birth risks and family recreation. The magazine shared ... Wednesday. ,Mayor Thomas M. Menino, while commenting on ...
    ... study finds that CT scans used in emergency rooms spotted ... MRI scans which are better in identifying any type of ... to magnetic resonance imaging,” wrote Dr. Geoffrey A. Donnan and ... note accompanying the study report. ,Doctors argue that ...
    ... project to revamp its healthcare infrastructure and train health ... expected to benefit over 45 million people. ,Health ... medical facilities at the village level and the project ... scheme would benefit over 45 million people at the ...
    Cached Medicine News:Health News:A Novel Technique Nudges Genes Into Activity 2Health News:A Novel Technique Nudges Genes Into Activity 3Health News:Under-Elevens Hurtle Towards Obesity, British MPs Call for Action 2Health News:Mega Project to Revamp Karnataka’s Healthcar 2
    ... A necessary addition to ... the Reichert Trial Frame ... and smooth controls for ... robust design, high-quality materials, ...
    ... The Ultramatic Rx Master is ... years of reliable service and ... that measurably improve procedures. It ... need and want most, including ...
    The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
    ... Illumination is provided by a cool-running, ... light only what you need to see ... best of all they are maintenance free ... light bulb. Every Phoroptor comes with a ...
    Medicine Products: